



June 15, 2015

## **Agile Therapeutics to Present at the JMP Securities Life Sciences Conference 2015**

### **Presentation Scheduled on Tuesday, June 23th, 2015 at 9:00 AM ET**

PRINCETON, N.J., June 15, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that [Al Altomari, President and Chief Executive Officer](#) will present at the JMP Securities Life Sciences Conference 2015 scheduled on Tuesday, June 23th, 2015 at 9:00 AM ET at the St. Regis Hotel in New York City.

To access the live and archived webcast of the presentation, visit the Investor Relations section of Agile Therapeutics website at [www.agiletherapeutics.com](http://www.agiletherapeutics.com). The webcast will be archived on Agile Therapeutics website for 60 days following the event.

### **About Agile**

Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla<sup>®</sup>, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion<sup>®</sup>, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at [www.agiletherapeutics.com](http://www.agiletherapeutics.com).

CONTACT: Mary Coleman 609-683-1880

Source: Agile Therapeutics

News Provided by Acquire Media